MedTrace Logo

Emtricitabine for Naive Chinese Chronic Hepatitis B Patients

NCT02327663 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2014-12-30

No results posted yet for this study

Summary

This study evaluates generic emtricitabine(FTC) in Chinese naive chronic hepatitis B patients. Patients were divided into 2 groups: HBeAg positive Chronic hepatitis B(CHB)group and HBeAg negative Chronic hepatitis B(CHB)group.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Emtricitabine

emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24

Sponsors & Collaborators

  • Beijing Ditan Hospital

    collaborator OTHER

  • Hebei Medical University Pharmaceutical Factory

    collaborator INDUSTRY

  • National Health and Family Planning Commission, P.R.China

    collaborator OTHER_GOV

  • Asian-Pacific Alliance of Liver Disease, Beijing

    lead OTHER

Principal Investigators

  • Jun Cheng, M.D. · Asian Pacific Alliance of Liver Diseases, Beijing

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-06-30
Completion
2017-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02327663 on ClinicalTrials.gov